Skip to main content

Drug Interactions between hydroxypropyl chitosan / terbinafine topical and Risperdal Consta

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

risperiDONE terbinafine

Applies to: Risperdal Consta (risperidone) and hydroxypropyl chitosan / terbinafine topical

MONITOR: Coadministration with terbinafine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by terbinafine, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent). A case of nortriptyline (a CYP450 2D6 substrate) intoxication corresponding to significantly increased serum drug concentrations was reported in a patient shortly after the addition of terbinafine. Rechallenge in the patient produced similar results.

MANAGEMENT: Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever terbinafine is added to or withdrawn from therapy. Due to the long elimination half-life of terbinafine, especially following prolonged use, such interactions may be observed for several months after discontinuation of terbinafine therapy.

References

  1. (2001) "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation
  2. Van der Kuy PH, Hooymans PM, Verkaaik AJ (1998) "Nortriptyline intoxication induced by terbinafine." BMJ, 316, p. 441
  3. AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL (1999) "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther, 65, p. 465-72
  4. Gupta AK, Katz HI, Shear NH (2000) "Terbinafine and potential drug interactions - Reply." J Am Acad Dermatol, 43, p. 883-4
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

risperiDONE food

Applies to: Risperdal Consta (risperidone)

GENERALLY AVOID: Risperidone oral solution is not compatible with either tea or cola. In addition, alcohol may potentiate some of the pharmacologic effects of risperidone. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Risperidone oral solution should not be mixed with tea or cola. It may be taken with water, coffee, orange juice, or lowfat milk. Patients should also be advised to avoid consumption of alcohol.

References

  1. (2001) "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer